## TECH: Bio-Techne Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.83 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates). Caution: momentum weakening (-3.1% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($59.28)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Russell Investments Group Ltd. Sells 23,984 Shares of Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251204T120935 | Somewhat-Bullish | Relevance: 100%
- Russell Investments Group Ltd. has reduced its stake in Bio-Techne Corp by selling 23,984 shares, leaving them with 142,902 shares valued at approximately $7.35 million. While Bio-Techne's recent quarterly EPS matched estimates, revenue fell short. The company maintains a "Moderate Buy" consensus rating from analysts with a target price of $70.92.

**2. Norges Bank Buys New Stake in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251204T114949 | Somewhat-Bullish | Relevance: 100%
- Norges Bank has purchased a new stake in Bio-Techne Corp (NASDAQ:TECH), acquiring 1,909,395 shares valued at approximately $98.24 million during the second quarter. This move makes Norges Bank a significant institutional investor in the biotechnology company, holding about 1.22% of Bio-Techne's stock. Other institutional investors also adjusted their positions in Bio-Techne, which recently announced a quarterly dividend of $0.08 per share and had analysts weigh in on its stock performance.

**3. Edgestream Partners L.P. Has $11.81 Million Holdings in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T105226 | Bullish | Relevance: 100%
- Edgestream Partners L.P. increased its stake in Bio-Techne Corp (NASDAQ:TECH) by 15.9% in Q2, now holding 229,625 shares valued at $11.81 million. Institutional investors own approximately 98.95% of the company, and analysts have a "Moderate Buy" rating with a consensus price target of $70.92. Bio-Techne reported $0.42 EPS in line with estimates and declared a quarterly dividend of $0.08 per share.

**4. Capital Fund Management S.A. Invests $4.89 Million in Bio-Techne Corp $TECH**
- Source: MarketBeat | 20251202T100713 | Somewhat-Bullish | Relevance: 100%
- Capital Fund Management S.A. recently acquired a new stake of 95,046 shares in Bio-Techne Corp (NASDAQ:TECH) valued at approximately $4.89 million during the second quarter. This investment makes Capital Fund Management S.A. a significant institutional holder, owning about 0.06% of Bio-Techne. The article also details other institutional investor activities, analyst ratings, and Bio-Techne's recent financial performance and dividend announcement.

**5. BioMarin Pharmaceutical Inc. (BMRN): A Bull Case Theory**
- Source: Finviz | 20251204T141500 | Somewhat-Bullish | Relevance: 62%
- BioMarin Pharmaceutical Inc. (BMRN) appears materially undervalued despite strong operational performance, with institutional ownership of 99.6% and consistent outperformance of analyst expectations. The company, trading near 52-week lows, reported significant EPS growth in Q2 2025 due to a successful restructuring, and management anticipates further benefits and has upgraded guidance. Its orphan drug portfolio faces limited competition and has upcoming clinical trial conclusions expected to lead to approvals, presenting a compelling investment opportunity despite a commonly cited competitive headwind.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Argus Research | $68 | $65 | +5% |
| 2025-11-06 | UBS | $70 | $65 | +8% |
| 2025-11-06 | Wells Fargo | $70 | $59 | +19% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Argus Research | main | Buy |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 3 ($0.43M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.5% (-2.7%)
- Blackrock Inc.: 7.6% (-2.3%)
- Morgan Stanley: 4.7% (+10.0%)
- State Street Corpora: 3.7% (-1.8%)
- Wellington Managemen: 3.3% (+349.8%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Analyst target momentum: 3 raises (avg +10%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.83 indicates undervaluation relative to growth. Forward P/E 29.2x stretched relative to 10% growth. Balance sheet: strong liquidity (4.2x), low leverage (D/E 0.29). Analyst sentiment positive (3 raises, avg +10%). Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.46 |
| 52W Range | $46.01 - $79.28 |
| Short Interest | 6.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.83 |
| Forward P/E | 29.2 |
| Current P/E | 32.2 |
| YoY Growth | 10.0% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 5.1% to 2.0% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 2.0pp (needs >4.0% for momentum thesis). MRS_5 (-0.7%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.1% shows strong absolute momentum above own 20MA. Outperforming sector by 3.4pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: -DLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.97% (CS: 68) | Neutral |
| RSI_14 | 56.8 | Neutral |
| MACD Histogram | 0.27 | Bullish |
| vs SMA20 | 1.041x | Above |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.145x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $63.54
- **Stop Loss:** $59.28 (6.7% risk)
- **Target:** $72.06 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 117
- **Position Value:** $7,434.18
- **Portfolio %:** 7.43%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-09 (Est: $0.43)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.42 | $0.42 | -0.4% |
| 2025Q2 | $0.50 | $0.53 | +5.8% |
| 2025Q1 | $0.51 | $0.56 | +10.4% |
| 2024Q4 | $0.39 | $0.42 | +7.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*